X. FUTURE SCOPE

- As in present study, the effect of different parameters on the release of Eterocoxib, celecoxib and Lornoxicam was tested and quantified; the parameters are required to be optimized to have the release rate within therapeutic window.

- The release rate is also required to be followed up to the complete release of drug so as to observe any deviation from zero-order release rate after depletion of undissolved drug in the tablet core.

- *In-vitro & In-vivo* evaluation of present study.

- *In vitro & In vivo* correlation of present study.

- Most of the currently marketed products are based on drugs used in long-term therapies for diabetes, hypertension, attention-deficit disorder, rheumatoid arthritis and other chronic disease states. Besides oral osmotic delivery systems, implants that work on osmotic principles are promising for delivery of a wide variety of molecules with a precise rate over a long period of time. Further, with the discovery of newer and potent drugs by the biotechnology industry, the need to deliver such compounds at a precise rate certainly will pave the way for osmotic delivery systems to play an increasingly important role in drug delivery.